Conclusion
The serum endocan levels failed to show a proportionate increase with increasing degree of SNHL, indicating that there is no precise association between SNHL and serum endocan levels. The serum endocan levels of patients with SNHL did not significantly differ from those of the healthy controls.
Methods
Patients with documented SNHL and healthy controls were included in the study, whereas those with a known history of chronic inflammatory condition were excluded. In addition, a recent history of use of glucocorticoids, nonsteroid anti-inflammatory drugs, or any ototoxic medications was also considered as an exclusion criterion due to its potential impact on endocan synthesis and metabolism. Following overnight fasting, blood samples were collected, and serum endocan levels were measured. For statistical analysis of the data, PASW Statistics for Windows version 18 was used.
Results
The comparison of the subgroups yielded no statistically significant difference between the control and mild-to-moderate SNHL groups. Despite the increase in hearing loss, the difference between the endocan levels in these patients did not increase proportionately and was not statistically significant (p>0.05). The patients in the severe SNHL group had a higher level of serum endocan than those in other groups, and the difference was statistically significant (p<0.05).